Pharma Focus Asia

CANAGLU® Tablets 100mg Approved for the Indication of Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus in Japan

Wednesday, June 22, 2022

Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Holdings Group, announced that has acquired an approval for partial changes to CANAGLU® Tablets 100mg (CANAGLU) (INN: canagliflozin) for the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus (excluding patients with end-stage renal disease or undergoing dialysis) on June 20.

Type 2 diabetes mellitus is a major risk factor for the development and progression of chronic kidney disease (CKD) and CKD complicated with type 2 diabetes mellitus is very common. In such patients, renal function decreases as the disease progresses, but if renal failure develops, dialysis therapy needs to be started. Dialysis therapy not only reduces patients’ quality of life (QOL) but also an important issue from the viewpoints of health economics.

The approval of the additional indication of CANAGLU will provide one option to resolve these issues and contribute to the improvement of QOL in patients with renal disease, along with VAFSEO, a treatment for renal anemia launched in 2020.

CANAGLU, discovered by MTPC, was approved in July 2014 in Japan as a treatment agent for type 2 diabetes mellitus and has been marketed since September 2014. It has also approved in Taiwan in March 2017. The additional indication of diabetic nephropathy was approved in February 2021 in Taiwan.

MTPC will continue to work tirelessly to bring new treatment options to patients who confront their illness.

Canagliflozin (Japan names: CANAGLU® Tablets 100mg)
Canagliflozin (INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) is an SGLT2 inhibitor that originated in Japan. It was discovered by Mitsubishi Tanabe Pharma and has its research roots in T-1095, the world’s first orally bioavailable sodium glucose co-transporter inhibitor. CANAGLU® inhibits SGLT2, a transporter involved in the reabsorption of glucose in the renal tubules of the kidneys, suppresses the reabsorption of glucose, promotes the excretion of excessive glucose into the urine, and as a result, lowers the blood glucose level.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024